Two Sigma Securities LLC Increases Stake in IDEXX Laboratories, Inc. $IDXX

Two Sigma Securities LLC grew its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 166.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,636 shares of the company’s stock after acquiring an additional 1,645 shares during the period. Two Sigma Securities LLC’s holdings in IDEXX Laboratories were worth $1,388,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. Aurora Investment Managers LLC. purchased a new position in shares of IDEXX Laboratories during the 2nd quarter valued at about $2,442,000. Elyxium Wealth LLC purchased a new stake in IDEXX Laboratories in the 4th quarter worth approximately $3,666,459,000. NewEdge Wealth LLC raised its stake in IDEXX Laboratories by 122.3% during the 4th quarter. NewEdge Wealth LLC now owns 6,597 shares of the company’s stock worth $4,463,000 after acquiring an additional 3,629 shares during the period. Prospera Financial Services Inc bought a new stake in IDEXX Laboratories during the 4th quarter worth approximately $4,188,000. Finally, Fortem Financial Group LLC purchased a new position in IDEXX Laboratories during the fourth quarter valued at approximately $2,068,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Wall Street Analyst Weigh In

IDXX has been the subject of a number of recent analyst reports. Wall Street Zen lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Sunday, July 12th. UBS Group lifted their target price on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the company a “neutral” rating in a research note on Wednesday, August 5th. Barclays dropped their target price on shares of IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating for the company in a report on Tuesday, August 11th. Weiss Ratings lowered IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Thursday. Finally, Citigroup raised their price target on IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a report on Wednesday, August 5th. Six equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $747.00.

IDEXX Laboratories Stock Performance

NASDAQ:IDXX opened at $556.69 on Tuesday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87. IDEXX Laboratories, Inc. has a 1 year low of $518.55 and a 1 year high of $769.98. The stock’s 50 day simple moving average is $559.23 and its two-hundred day simple moving average is $572.70. The company has a market cap of $43.86 billion, a price-to-earnings ratio of 39.15, a PEG ratio of 2.96 and a beta of 1.54.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, beating analysts’ consensus estimates of $3.94 by $0.33. IDEXX Laboratories had a return on equity of 71.96% and a net margin of 25.03%.The firm had revenue of $1.22 billion during the quarter, compared to the consensus estimate of $1.20 billion. During the same period in the prior year, the company earned $3.50 EPS. The company’s quarterly revenue was up 9.7% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. As a group, equities analysts anticipate that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current fiscal year.

About IDEXX Laboratories

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.